Dr. Rakesh Patel, MD
Claim this profilePMG Research of Salisbury
Studies Diabetes
Studies Rheumatoid Arthritis
10 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Rakesh Patel, MD is currently running
Ianalumab
for Sjogren's Syndrome
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 or CVAY736A2302). * The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe for injection. All participants will receive ianalumab either monthly or every 3 months. * The treatment duration will be 3 years with an additional up to 2-year safety follow-up. The total duration of this extension study will be up to 5 years. * The visit frequency will be monthly during both the treatment period and mandatory follow-up, and then less frequently during the subsequent conditional follow-up Treatment of interest: The randomized treatment (ianalumab) will be received monthly or every 3 months. Participants assigned to treatment every 3 months will receive placebo every month between the ianalumab doses to maintain blinding. Number of Participants: Approximately 600 participants from the NEPTUNUS core studies will be rolled over into the extension study. Treatment Groups:There will be no screening period in this trial. From Week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. From Week 52 of the NEPTUNUS core studies (i.e., Day 1 in the extension study), eligible participants will be assigned to either one of the treatment regimens: * ianalumab 300 mg monthly or * ianalumab 300 mg once every 3 months Participants receiving placebo in either of the NEPTUNUS core studies will be randomized 1:1 to receive ianalumab 300 mg monthly or every 3 months starting from Week 60 and participants receiving ianalumab in either of the NEPTUNUS core studies will continue the same treatment in the extension study. Ianalumab will be given as a subcutaneous injection from a 2 mL pre-filled syringe. Participants will be given the opportunity to self-inject at home on some visits after receiving training.
Recruiting1 award Phase 33 criteria
LY3871801
for Rheumatoid Arthritis
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Recruiting0 awards Phase 2
More about Rakesh Patel, MD
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rakesh Patel, MD has experience with
- Pegloticase
- Eversense CGM System
- Blood Glucose Meter
- LY3871801
- Placebo
- Ianalumab (VAY736)
Breakdown of trials Rakesh Patel, MD has run
Diabetes
Rheumatoid Arthritis
Sjogren's Syndrome
Sjögren's Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rakesh Patel, MD specialize in?
Rakesh Patel, MD focuses on Diabetes and Rheumatoid Arthritis. In particular, much of their work with Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Rakesh Patel, MD currently recruiting for clinical trials?
Yes, Rakesh Patel, MD is currently recruiting for 3 clinical trials in Salisbury North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Rakesh Patel, MD has studied deeply?
Yes, Rakesh Patel, MD has studied treatments such as Pegloticase, Eversense CGM System, Blood glucose meter.
What is the best way to schedule an appointment with Rakesh Patel, MD?
Apply for one of the trials that Rakesh Patel, MD is conducting.
What is the office address of Rakesh Patel, MD?
The office of Rakesh Patel, MD is located at: PMG Research of Salisbury, Salisbury, North Carolina 28144 United States. This is the address for their practice at the PMG Research of Salisbury.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.